Cargando…
“One pill, once daily”: what clinicians need to know about Atripla™
As the number of persons chronically prescribed antiretrovirals has grown and the realization that antiretrovirals are required to be continued for life, pharmaceutical manufacturers have developed new classes of agents, improved the pharmacokinetics of marketed products through dosing reformulation...
Autores principales: | Clay, Patrick G, Taylor, Tracey AH, Glaros, Alan G, McRae, MaryPeace, Williams, Charlott, McCandless, Don, Oelklaus, Maurice |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504066/ https://www.ncbi.nlm.nih.gov/pubmed/18728842 |
Ejemplares similares
-
Atripla™ – HIV therapy in one pill
por: Julg, Boris, et al.
Publicado: (2008) -
Opioid and neuroHIV Comorbidity – Current and Future Perspectives
por: Fitting, Sylvia, et al.
Publicado: (2020) -
An update on the use of Atripla(®) in the treatment of HIV in the United States
por: Horberg, Michael A, et al.
Publicado: (2010) -
Application of infrared matrix-assisted laser desorption electrospray ionization mass spectrometry for morphine imaging in brain tissue
por: Desyaterik, Yury, et al.
Publicado: (2023) -
Atripla(R)/anti-TB combination in TB/HIV patients. Drug in focus
por: Semvua, Hadija H, et al.
Publicado: (2011)